From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Methods for EGFR mutation testing (n = 181) | n (%) |
Therascreen EGFR Mutation Test kit (ARMS) (Qiagen) | 85 (47.0) |
RT-PCR (not specified) | 26 (14.4) |
Fluorescent PCR fragment length analysis | 22 (12.2) |
Direct sequencing | 20 (11.0) |
Cobas EGFR Mutation Test kit (Roche) | 9 (5.0) |
Allelic discrimination using fluorogenic probes | 4 (2.2) |
Digital PCR | 2 (1.1) |
Double PCR | 1 (0.6) |
Non specified | 16 (8.8) |
Sample characteristics | n (%) |
Biopsy (n = 121) | 123 (68.7) |
Tumor tissue source | |
Primary tumor | 94 (77.7) |
Metastatic sites | 27 (22.3) |
Cytology (n = 55) | 55 (30.7) |
Tumor tissue source | |
Primary tumor | 35 (63.6) |
Metastatic sites | 20 (36.4) |
Biopsy and cytology type (n = 174) | |
Bronchoscopy | 74 (42.5) |
FNA | 56 (32.2) |
Thoracocentesis | 16 (9.2) |
Surgery | 14 (8.0) |
Biopsy (unspecified) | 8 (4.6) |
Videothoracoscopy | 5 (2.9) |
Tru-cut | 4 (2.3) |
EBUS | 1 (0.6) |
Data not available | 2 (1.1) |